ARROWHEAD PHARMACEUTICALS, INC. 8-K

What Happened Arrowhead Pharmaceuticals (ARWR) announced on June 12, 2026 that its Board appointed Dr. Matt Cohen, M.D., M.B.A., as a director, effective that same day. Dr. Cohen brings more than 25 years of healthcare investing and portfolio management experience; he currently serves as Managing Director at Vida Ventures (joined in 2025) and was a portfolio manager and lead growth-focused healthcare investor at J.P. Morgan Asset Management from 2005 until 2025. He holds an M.D. from McGill University and an M.B.A. from NYU Stern.

Key Details

• Appointment effective date: June 12, 2026.
• Sign-on equity grant: restricted stock units valued at $887,000, scheduled to vest over three years.
• Compensation: will receive standard non-employee director cash and equity compensation as described in Arrowhead’s January 27, 2026 Proxy Statement; will enter the company’s standard indemnity agreement.
• No family relationships or arrangements with Arrowhead’s directors or officers were reported.

Why It Matters This is a board-level appointment (non-executive) that adds significant healthcare investing and portfolio management experience to Arrowhead’s governance team, which may aid oversight of strategy and capital allocation decisions. The equity grant aligns Dr. Cohen’s financial interests with shareholders over a multi-year vesting schedule. There are no disclosed related-party concerns based on the filing. Investors may watch for any future proxy disclosures or governance updates for additional context.